Mittra R A, Huynh L T, Ruttum M S, Mieler W F, Connor T B, Han D P, Pulido J S, Dev S
Eye Institute, Vitreoretinal Section, Medical College of Wisconsin, Milwaukee 53226, USA.
Arch Ophthalmol. 1998 Sep;116(9):1190-4. doi: 10.1001/archopht.116.9.1190.
To determine the visual outcome after surgery for persistent hyperplastic primary vitreous using modern vitreoretinal techniques.
Retrospective medical record review during a 5-year period (June 1992 to June 1997). Information recorded for each patient included age, medical history, sex, results of preoperative ocular examination, age at diagnosis, procedure performed, intraoperative and postoperative complications, location and number of sclerotomy sites, type of aphakic rehabilitation, amblyopic therapy given, final visual acuity, and length of follow-up.
Fourteen patients who underwent surgical management of combined anterior and posterior persistent hyperplastic primary vitreous were identified. Eleven patients underwent aphakic rehabilitation and aggressive amblyopic therapy consisting of occlusive therapy for several waking hours each day. One additional older patient received aphakic rehabilitation only. Ten eyes (71%) achieved a visual acuity of 20/300 or better, and 8 (57%) obtained a final visual acuity of 20/100 or better. Average length of follow-up was 22 months (range, 4-57 months). Nine patients were fitted with an aphakic soft contact lens, 2 older patients had a posterior chamber intraocular lens placed at the time of vitrectomy, and 1 patient wore aphakic spectacles.
With modern vitreoretinal techniques, aphakic rehabilitation, and aggressive amblyopic therapy, useful vision can be obtained in the majority of patients with combined anterior and posterior persistent hyperplastic primary vitreous.
运用现代玻璃体视网膜技术确定持续性增生性原发性玻璃体手术后的视力预后。
对5年期间(1992年6月至1997年6月)的病历进行回顾性研究。记录的每位患者信息包括年龄、病史、性别、术前眼部检查结果、诊断时年龄、所行手术、术中及术后并发症、巩膜切开部位的位置和数量、无晶状体眼的康复类型、给予的弱视治疗、最终视力及随访时间。
确定了14例接受了前后部联合持续性增生性原发性玻璃体手术治疗的患者。11例患者接受了无晶状体眼康复及积极的弱视治疗,包括每天清醒时数小时的遮盖治疗。另外1例老年患者仅接受了无晶状体眼康复治疗。10只眼(71%)视力达到20/300或更好,8只眼(57%)最终视力达到20/100或更好。平均随访时间为22个月(范围4 - 57个月)。9例患者佩戴了无晶状体软性接触镜,2例老年患者在玻璃体切除时植入了后房型人工晶状体,1例患者佩戴无晶状体眼镜。
通过现代玻璃体视网膜技术、无晶状体眼康复及积极的弱视治疗,大多数前后部联合持续性增生性原发性玻璃体患者可获得有用视力。